Global value dossier for treatment in breast cancer
Data collection of costs associated with breast cancer care
Manuscript on the German model for a hormonal drug used in the treatment of breast cancer
Development of two budget impact models in breast cancer with population data by city
Two budget impact models for Italy for an injectable chemotherapy drug for breast cancer
Budget impact model in breast cancer for France
Development of a cost-calculator for a biosimilar for breast cancer
Payer value deck in breast cancer
Payer value deck update for a breast cancer biosimilar
Burden of disease deck in breast cancer
Response to payer questions in breast cancer
Response to payer questions update for a breast cancer biosimilar
Burden of disease deck and frequently asked questions deck in breast cancer biosimilars
One-pager communication in a breast cancer biosimilar
Productivity and QoL study in breast cancer
Literature review and consultancy on breast cancer
e-v@luate platforms in breast cancer
Market access training and workshop on breast cancer
Primary research of fixed dose combinations pricing in breast cancer
HER2 positive breast cancer
Literature review of productivity data in HER2 positive breast cancer
Budget impact model for a biosimilar in HER2 breast cancer
Advanced breast cancer
Development of a perceived tolerability questionnaire in first line treatment of advanced breast cancer
Strategy for an injectable chemotherapy drug for advanced breast cancer and submission to NICE/SMC
Budget impact model and analysis for an injectable chemotherapy drug for advanced breast cancer in 5 EU countries
Economic evaluation of a therapy for postmenopausal women with advanced breast cancer (with the perspective of 3rd party national and local payers in the UK)
Development and population of an economic model in advanced breast cancer
Conference poster on a cost utility analysis of two treatments for advanced breast cancer
Conference poster on the economic evaluation of a therapy for postmenopausal women with advanced breast cancer
Phase IV non-interventional prospective observational study comparing patient reported outcomes in advanced breast cancer
PRO label review manuscript development in advanced/metastatic breast cancer
Metastatic breast cancer
Value dossier and e-v@luate platform in metastatic breast cancer
Scientific communication of cost-effectiveness analysis in metastatic breast cancer
PRO knowledge base instruments and methods library for metastatic breast cancer
Update to a Health Impact Projection (HIP) model in metastatic triple negative breast cancer
Triple negative breast cancer
Global value dossier and upload to e-v@luate platform in triple negative breast cancer
Data analyses on a multi-indication budget impact model and cost utility model in triple negative breast cancer
Payer value tool in triple negative breast cancer (TNBC)
Standalone budget impact models in triple negative breast cancer
Update to a Health Impact Projection (HIP) model in neo-adjuvant triple negative breast cancer
Global value dossier for treatment in gastric cancer
Development of a cost-calculator for a biosimilar for gastric cancer
Review of a SMC submission for a chemotherapy drug for advanced gastric cancer
Burden of disease deck, payer value dossier deck and frequently asked questions deck in gastric cancer
Payer value deck in 1st line gastric cancer
Response to payer questions in 1st line gastric cancer
Literature and PRO strategy for gastric oesophageal cancer
Literature review and development of a PRO strategy for gastric cancer
Statistical analyses to support HRQoL in gastric cancer, and estimation of EQ-5D utilities for an Asian population in a trial based on existing data and non-Asian trial utility data
Advisory board attendance and presentation for utilities in gastric cancer and illustrative summary analyses
Utilities analyses to support economic modelling in gastric cancer
Updates to a Health Impact Projection (HIP) model in gastric cancer
Exploring physicians’ perceptions of adherence levels, reasons for non-adherence, and opinions of how to improve adherence in leukaemia patients receiving treatment
Patient satisfaction in chemotherapy for leukaemia
Acute lymphoblastic leukaemia
Support in IRB submissions and scientific dissemination in acute lymphoblastic leukaemia
Burden of refractory acute lymphoblastic leukaemia on patients and caregivers
Acute myeloid leukaemia (AML)
Global value dossier and e-v@luate platform for a treatment in AML
Global value dossier, conference poster and medical writing support in AML
Quality of life analysis in the treatment of AML
Payer evidence council value communication materials (booklet, slides and Q&A) to inform phase III trial design in AML
Cost-effectiveness analysis and budget impact analysis for a prognostic and minimal residual genetic tests for AML
Systematic literature review of healthcare resource utilisation in AML
Literature review of resource utilisation in AML
Strategic consulting on AML
Health-related quality of life in elderly patients with AML: Position paper on an AML treatment for inclusion in a value dossier
Qualitative research to understand the value of extended overall survival to AML patients
Chronic lymphocytic leukaemia (CLL)
Utility study in advanced CLL
Abstract and manuscript on utility study results in CLL
Payer evidence dossiers for treatments of CLL
Mixed treatment comparison and training meeting on a global value dossier for a treatment for CLL
Health state preference study mapping the change over the course of the CLL disease process
Conference poster on the health state preference study mapping the change over the course of the CLL disease process
Global value dossier for a treatment in CLL
Statistical analysis plans and provision of PRO support to the client for their trials of a biological therapy cancer treatment for CLL
General consultancy agreement to review PRO measures in CLL
Analysis of PRO data from the CLL registry
Manuscript on a budget impact model for a cross-indication biosimilar in CLL
Chronic myeloid leukaemia (CML)
Value dossier support in CML linking myelosuppression with quality of life impact
Value dossier support in CML linking response to utilities and additional analysis
Critical review of PRO instruments in CML
Adverse event to PRO linking in CML
Manuscript on AE-PRO linking in CML
Targeted literature review and manuscript on factors associated with adherence in CML
Development of a link between side effects and PROs in CML – a univariate approach
Preparation of 3 existing manuscripts on lung cancer for submission
Literature search and analysis of phase 2 vs phase 3 lung cancer studies
Literature and reimbursement review of intravenous versus subcutaneous therapies in lung cancer
Development of a pan-lung oncology treatment model
Landscape analysis for ablation in lung cancer
Patient interviews in lung cancer
Analyses of endpoints in oncology: Statistical analyses in lung cancer
Analyses of endpoints in oncology: Country-specific EQ-5D utilities in lung cancer
Analytical evidence for improvement in symptoms and quality of life in lung cancer patients on a specified treatment
Analytical evidence for improvement in symptoms and quality of life in pre and post-randomisation lung cancer patients (by age groups)
Strategic consulting, research and measurement in solid tumours
Strategic communications planning in lung cancer
Consulting for an FDA submission in lung cancer
Summary presentation of a workstream in lung cancer
Updates to a Health Impact Projection (HIP) model in extensive 1st line SCLC, locally advanced or metastatic 2nd line NSCLC, and metastatic 1st line NSCLC
Non-small cell lung cancer (NSCLC)
Global value dossier and e-v@luate platform in NSCLC
Global value dossier and e-v@luate platform in non-squamous NSCLC
Global value dossier and e-v@luate platform in advanced squamous NSCLC
Global value dossier for a treatment in metastatic NSCLC
Payer value deck and response to payer questions update in 1st line NSCLC
Updated payer value dossier deck and FAQs deck for 1st line NSCLC
Updated burden of disease decks, payer value dossier decks and FAQs decks for 1st line and 2nd line NSCLC
Societal costs, health-related quality of life systematic literature review and publications plan for NSCLC in Europe
Literature review of overall survival and bone metastases in NSCLC
Literature review to inform global market access materials in NSCLC
Structured literature review in advanced 1st line NSCLC
Systematic review and mixed treatment comparison in advanced NSCLC
Development of technical documentation and manuscript on NSCLC
Two manuscripts on the indirect comparison of the efficacy of two different therapies for NSCLC
Development of a manuscript on the cost-effectiveness of a treatment in NSCLC in Italy
Manuscript on the efficacy of three different drugs for the treatment of NSCLC
Model review of a drug used in the treatment of NSCLC
Multi-indication budget impact model in NSCLC
Adaptation of a multi-indication value-based pricing model in NSCLC to China
Value-based model in NSCLC
Update to a Belgian value-based pricing model in NSCLC
Standardisation of economic models in NSCLC
Global model update and country adaptations for a multi-indication value-based pricing (VBP) model on NSCLC
Burden of disease decks in advanced 1st line and 2nd line NSCLC
Burden of disease deck update in 1st line NSCLC
Integrated research plan in advanced melanoma and NSCLC
Value slide deck for treatment in NSCLC
Guidance documents for affiliates in treatment for NSCLC
Situational analysis report of epidermal growth factor receptor (EGFR) predictive testing in NSCLC
Communication toolkit for a lung cancer supplement
Companion diagnostics biomarker FAQs compilation deck in NSCLC
FAQs update in advanced 1st line NSCLC
FAQs deck update in 2nd line NSCLC
Payer slide decks and objection handler in NSCLC
Payer tools implementation guide in NSCLC
Payer value proposition deck update in 2nd line NSCLC
Payer value deck update in advanced 1st line NSCLC
Payer value deck and response to payer questions update in 1st line NSCLC
HTA submission support in epidermal growth factor receptor positive (EGFR+) and non-small cell lung cancer (NSCLC)
Value communication for a matching-adjusted indirect comparison (MAIC) in NSCLC
Abstract and manuscript on MAIC in NSCLC
Deep-dive trial design in NSCLC
Numerous abstracts and conference posters on NSCLC, advanced NSCLC and related treatments
Several abstracts and conference posters relating to the cost and cost effectiveness of a first-line treatment option for patients with NSCLC
Abstract and poster on progression-free survival and overall survival in patients with NSCLC
Literature review of outcomes and costs during treatment for advanced NSCLC
Literature review and consultancy on NSCLC
Manuscript on stage IIIb and IV NSCLC
Development of a measurement dossier in advanced NSCLC for the EMA
Meta-analysis and manuscript on stage IIIb and IV NSCLC
Development of posters for a MAIC in advanced NSCLC
Epidemiology evidence, patient pathway modelling and literature review in advanced NSCLC
Statistical analyses of clinical trial data (safety study) in NSCLC
Statistical analyses of clinical trial data (observational study) in NSCLC
Clinical trial analyses to support health-related quality of life in first-line NSCLC
Qualitative study on the needs and preferences of patients with advanced NSCLC for maintenance therapy
Development of an analysis plan in NSCLC for the USA and Europe
Analysis of PRO data in NSCLC
Qualitative interviews to understand the impact of NSCLC on quality of life and on caregivers and family members
EQ-5D review for an EMA measurement dossier in advanced NSCLC
Exploratory qualitative interviews in NSCLC patients to assess progression-free survival
Comparative effectiveness of two treatments for the treatment of NSCLC
Feasibility network meta-analysis comparison of two treatments for NSCLC
Exploratory analysis of the Visual Symptom Assessment Questionnaire (VSAQ) in patients who have undergone treatment for NSCLC
Utilities analyses to support economic modelling in NSCLC
Clinical trial analyses to support health-related quality of life in NSCLC
Impact of whole brain radiation therapy in patients with NSCLC with brain metastases
Small cell lung cancer (SCLC)
Global value dossier and upload to e-v@luate platform in SCLC
AMCP dossier in SCLC
Systematic literature reviews for the societal and health-related quality of life burden of SCLC
Systematic literature review and manuscript on real-world effectiveness and tolerability of treatments in SCLC
Literature review on real-world effectiveness and tolerability of treatment in SCLC
Utility study in SCLC
Development of a budget impact model in SCLC
Budget impact model in 1st line SCLC
Development of a disease conceptual model and endpoint recommendation for SCLC
Phase IV clinical trial analysis of two drugs used in the treatment of SCLC
Analysis of symptoms for a drug used to treat SCLC
Full text reports on the longitudinal analyses of a drug used to treat SCLC for EU submission
Literature and PRO strategy for SCLC
Clinical trial analyses to support health-related quality of life in SCLC
Development of a budget impact model for primary mediastinal B-cell lymphoma (PMBCL)
Literature review and preparation of a PRO strategy in large B-cell lymphoma
Burden of diffuse large B-cell lymphoma on patients and caregivers
e-v@luate platform in diffuse large B-cell lymphoma
Hodgkin’s lymphoma
Payer evidence dossiers in non-Hodgkin’s lymphoma
Early payer engagement deck in classical Hodgkin’s lymphoma
Analyses of endpoints in oncology: Statistical analyses in Hodgkin’s lymphoma
Clinical trial analyses to support health-related quality of life in Hodgkin’s lymphoma
Non-Hodgkin’s lymphoma
Update of a payer evidence dossier in non-Hodgkin’s lymphoma
Literature review and conceptual mapping in non-Hodgkin’s lymphoma
Strategic PRO endpoint support, gap analysis and patient interviews in a biological therapy treatment for non-Hodgkin’s lymphoma
Validation of a patient satisfaction questionnaire in non-Hodgkin’s lymphoma
Conference poster and slide deck on non-Hodgkin’s lymphoma
Manuscript on a budget impact model for a cross-indication biosimilar in diffuse large B-Cell lymphoma, follicular lymphoma, follicular non-Hodgkin’s lymphoma
Lymphomas (other)
Core value dossier and value proposition in cutaneous T-cell lymphoma
Development of a budget impact tool for a treatment for chronic lymphatic lymphoma for Spain
Support programme for reimbursement submissions in cutaneous T-cell lymphoma
Strategic consulting for a lymphoma trial
Clinical trial analysis of health-related quality of life data in patients with previously untreated follicular lymphoma
Manuscript on a budget impact model for a cross-indication biosimilar in diffuse large B-Cell lymphoma, follicular lymphoma, and follicular non-Hodgkin’s lymphoma
Adaptation of a multi-indication value-based pricing model in melanoma to China
Literature review in metastatic melanoma treatment patterns
Scientific communication of a systematic literature review on caregiver burden in advanced metastatic melanoma
Global value dossier for a treatment in melanoma
Development of global market access materials (disease burden slide deck, payer value story and FAQs) in metastatic melanoma to support local access teams
Payer slide decks and objection handler update in metastatic melanoma
Implementation guide in metastatic melanoma
Burden of disease deck update in ipi refractory and ipi naïve advanced melanoma
Payer value proposition deck update in ipi refractory advanced melanoma
Payer value proposition deck update in ipi naïve advanced melanoma
Updated implementation guide in melanoma
Frequently asked questions deck in ipi refractory and ipi naïve advanced melanoma
Updated burden of disease deck, payer value dossier decks and obstacle handler in a treatment for refractory & naïve melanoma
Development of a budget impact model for adjuvant melanoma
KOL interviews and primary research into treatment patterns in adjuvant melanoma
Payer value deck and response to payer questions in adjuvant melanoma
Payer value deck and response to payer questions update in advanced melanoma
Burden of disease deck in adjuvant melanoma
Burden of disease and payer value deck in adjuvant and advanced melanoma
Standardization of economic models in melanoma
Value-based model in melanoma
Multi-indication budget impact model in melanoma
Global model update and country adaptations for a multi-indication value-based pricing (VBP) model on melanoma
Adaptation of a value-based pricing multi-indication global model in oncology to Greece
Strategic communications planning in melanoma
Update to a Belgian value-based pricing model in melanoma
Updates to a Health Impact Projection (HIP) model in adjuvant melanoma and unresectable or metastatic melanoma
Preparation of a genomics methods paper in melanoma
Summary presentation of a workstream in melanoma
Caregiver burden in advanced melanoma
Caregiver burden in melanoma in the EU
Evidence synthesis on the comparative effectiveness of systemic therapies for unresectable stage IIIc and stage IV melanoma
Pilot patient interviews in melanoma
Exploratory analyses of endpoints in oncology: Statistical analyses in melanoma
Analyses of endpoints in oncology: Statistical analyses in first-line melanoma
Clinical trial analyses to support the relationship between adverse events and health-related quality of life, health status and work productivity in melanoma
Clinical trial analyses to support health-related quality of life in melanoma: AMNOG analyses for combination arm therapy
Network meta-analysis on the efficacy of first line treatment for unresectable stage IIIC/IV melanoma
AMNOG analyses to support health-related quality of life in melanoma
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsRead MoreACCEPTREJECT
Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
We’d like to set analytic software i.e. Google Analytics/Click Dimensions to help us improve our website by collecting and reporting information on how you use it. The cookies collect information in a way that does not directly identify anyone. For more information on how these cookies work, please see our Cookies Policy.